3’UTR Polymorphism in ACSL1 Gene Correlates with Expression Levels and Poor Clinical Outcome in Colon Cancer Patients
Teodoro Vargas(Madrid Institute for Advanced Studies), Ana Ramı́rez de Molina(Madrid Institute for Advanced Studies), Juan Moreno‐Rubio(Hospital La Paz Institute for Health Research), Paloma Cejas(Dana-Farber Cancer Institute), Susana Molina(Madrid Institute for Advanced Studies), Roberto Martín‐Hernández(Madrid Institute for Advanced Studies), Jesús Herránz(Madrid Institute for Advanced Studies), Guillermo Reglero(Madrid Institute for Advanced Studies), Ana Custodio(Hospital Universitario La Paz), M. De Miguel(Hospital Universitario La Paz), Jaime Feliú(Hospital Universitario La Paz), Emilio Burgos(Hospital Universitario Infanta Sofía), Marta Mendiola(Hospital Universitario La Paz)
Cited by 39
Related Papers
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
|Cancer Discovery|2021|286
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
|Cancer Research|2020|215